- Home
- PETS vs EQ Comparison
PETS vs EQ Comparison
Compare PETS & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PETS
- EQ
- Stock Information
- Founded
- PETS 1996
- EQ 2017
- Country
- PETS United States
- EQ United States
- Employees
- PETS N/A
- EQ N/A
- Industry
- PETS Retail-Drug Stores and Proprietary Stores
- EQ Biotechnology: Pharmaceutical Preparations
- Sector
- PETS Consumer Staples
- EQ Health Care
- Exchange
- PETS Nasdaq
- EQ Nasdaq
- Market Cap
- PETS 57.8M
- EQ 57.8M
- IPO Year
- PETS N/A
- EQ 2018
- Fundamental
- Price
- PETS $1.99
- EQ $1.06
- Analyst Decision
- PETS Sell
- EQ Hold
- Analyst Count
- PETS 1
- EQ 1
- Target Price
- PETS $3.20
- EQ $1.00
- AVG Volume (30 Days)
- PETS 176.5K
- EQ 407.3K
- Earning Date
- PETS 11-03-2025
- EQ 11-13-2025
- Dividend Yield
- PETS N/A
- EQ N/A
- EPS Growth
- PETS N/A
- EQ N/A
- EPS
- PETS N/A
- EQ N/A
- Revenue
- PETS $226,972,000.00
- EQ $4,392,000.00
- Revenue This Year
- PETS N/A
- EQ N/A
- Revenue Next Year
- PETS $2.98
- EQ N/A
- P/E Ratio
- PETS N/A
- EQ N/A
- Revenue Growth
- PETS N/A
- EQ N/A
- 52 Week Low
- PETS $1.93
- EQ $0.27
- 52 Week High
- PETS $6.85
- EQ $2.35
- Technical
- Relative Strength Index (RSI)
- PETS 34.39
- EQ 41.42
- Support Level
- PETS $1.93
- EQ $1.31
- Resistance Level
- PETS $2.92
- EQ $1.58
- Average True Range (ATR)
- PETS 0.16
- EQ 0.14
- MACD
- PETS -0.04
- EQ -0.04
- Stochastic Oscillator
- PETS 6.57
- EQ 36.27
About PETS PetMed Express Inc.
PetMed Express Inc along with its subsidiaries is a nationwide pet pharmacy. The company markets prescription and non-prescription pet medications, health products, and supplies for dogs and cats, direct to the consumer. The company generates its revenue by selling pet medications and pet supplies mainly to retail consumers.
About EQ Equillium Inc.
Equillium Inc is a clinical-stage biotechnology company engaged in developing novel therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company intends to commercialize its product candidates either independently or through partnerships, or otherwise monetize its pipeline through strategic transactions. Itolizumab (EQ001), a clinical-stage product candidate, is an anti-CD6 immune-modifying monoclonal antibody, or mAb, that selectively targets the CD6-ALCAM signaling pathway to downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining a balanced immune response. The company's other clinical-stage and pre-clinical-stage candidates include EQ101 and EQ302.